NEW YORK, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the Company will give an oral presentation of data at the American Society of Human Genetics (ASHG) 2019 Annual Meeting in Houston (October 15-19) on AT-007, a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI) in Phase 1/2 development for treatment of Galactosemia. In addition, the Company will host an ASHG Educational Symposium featuring a panel of Galactosemia experts.
Details on the Oral Presentation and Educational Symposium are below:
Oral Presentation
Title: AT-007, a Novel CNS Penetrant Aldose Reductase Inhibitor Prevents the Metabolic and Tissue Specific Abnormalities of Galactosemia, in a GALT Deficient Rat Model of DiseaseDate and Time: Saturday, October 19, 2019, 8:30-8:45am CTPresenter: Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied TherapeuticsSession: 99Location: Room 370A Level 3/Convention Center
The presentation will be available on the ASHG conference website as well as the Applied Therapeutics website following the session.
Galactosemia Educational Symposium
Title: Development of an Oral Treatment for GalactosemiaDate and Time: Thursday, October 17, 2019, 12:45-2:00pm CTLocation: Marriott Marquis Houston, Room Briargrove AB, Level 3Key Topics:
Additional details for the event can be found here.
About Galactosemia Galactosemia is a rare metabolic disease that affects how the body processes a simple sugar called galactose, and for which there is no known cure or approved treatment available. Galactose is found in foods, but the human body also naturally produces galactose on its own, so dietary restriction cant prevent complications of disease. It is estimated that the U.S. Galactosemia population is approximately 2,800 patients, based on newborn screening data identifying 2,500 infants through 2014, and the estimated birth rate of 80 patients per year. High levels of galactose circulating in the blood and tissues of Galactosemia patients enables Aldose Reductase to convert galactose to a toxic metabolite, called galactitol, which causes long-term complications ranging from CNS dysfunction to cataracts.
About AT-007AT-007 is a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI) in Phase 1/2 development for treatment of Galactosemia. AT-007 has been studied in in an animal model of Galactosemia, which demonstrated that AT-007 reduces toxic galactitol levels and prevents disease complications.Applied Therapeuticsis conducting a biomarker based development program in patients with Galactosemia, based on the recently released draft industry guidance on drug development for low prevalence, slowly progressing rare metabolic diseases. The company received Orphan Designation for AT-007 for Galactosemia inMay 2019.
About Applied TherapeuticsApplied Therapeuticsis a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The companys lead drug candidate, AT-001, is a novel aldose reductase inhibitor (ARI) that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The company initiated a Phase 3 registrational study in DbCM inSeptember 2019.Applied Therapeuticsis also developing AT-007, a central nervous system penetrant ARI, for the treatment of Galactosemia, a rare pediatric metabolic disease, and initiated a Phase 1/2 clinical trial inJune 2019. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, expected to advance into a Phase 1 study in 2020.
Forward-looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as "may," "will," "expect," "anticipate," "plan," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are forward-looking statements. These include, without limitation, statements regarding(i) the design, scope and results of our clinical trials, (ii) the timing of the initiation and completion of our clinical trials, (iii) the likelihood that data from our clinical trials will support future development of our product candidates, (iv) the likelihood of obtaining regulatory approval of our product candidates and qualifying for any special designations, such as orphan drug designation, (v) our cash runway and the timing of our clinical development plan.Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved. Such risks and uncertainties include, without limitation, the uncertainties inherent in the initiation, execution and completion of clinical trials, in the timing of availability of trial data, in the results of the clinical trials, in the actions of regulatory agencies, in the commercialization and acceptance of new therapies. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with theU.S. Securities and Exchange Commission, including the Risk Factors contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Contacts
Investors:Maeve Conneighton(212) 600-1902 orappliedtherapeutics@argotpartners.com
Media:Brittany Horowitz(212) 704-4466 ormedia@appliedtherapeutics.com
Read the original:
Applied Therapeutics to Present Data Highlighting AT-007 for the Treatment of Galactosemia at the American Society of Human Genetics (ASHG) 2019...
- Myriad Genetics Get 2 Patents for Molecular Residual Disease Assay - February 7th, 2025
- Heredity - DNA, Genes, Inheritance | Britannica - January 6th, 2025
- Comparing Genetics and Molecular Genetics: What's the Difference? - December 19th, 2024
- Standards and guidelines for the interpretation of sequence ... - PubMed - December 19th, 2024
- Chapter 12: Techniques of Molecular Genetics - Biology LibreTexts - December 19th, 2024
- 8.S: Techniques of Molecular Genetics (Summary) - December 19th, 2024
- Master of Science Computational Biology and Quantitative Genetics - December 19th, 2024
- Pitt Researchers Lead Group that Calls for Global Discussion About Possible Risks from Mirror Bacteria - Pitt Health Sciences - December 19th, 2024
- Molecular Genetics Testing - StatPearls - NCBI Bookshelf - November 16th, 2024
- Working with Molecular Genetics (Hardison) - Biology LibreTexts - November 16th, 2024
- Molecular Underpinnings of Genetic and Rare Diseases: From ... - Frontiers - November 16th, 2024
- The molecular genetics of schizophrenia: New findings promise new insights. - November 16th, 2024
- 8: Techniques of Molecular Genetics - Biology LibreTexts - September 4th, 2024
- 1.5: Molecular Genetics - Biology LibreTexts - September 4th, 2024
- Molecular genetics made simple - PMC - National Center for ... - September 4th, 2024
- 4 Introduction to Molecular Genetics - University of Minnesota Twin Cities - September 4th, 2024
- Molecular genetics - Definition and Examples - Biology Online - September 4th, 2024
- A Detailed Look at the Science of Molecular Genetics - KnowYourDNA - September 4th, 2024
- Molecular Genetics | NHLBI, NIH - September 4th, 2024
- Molecular biology - Wikipedia - September 4th, 2024
- Genetics, Molecular & Cellular Biology Admissions - September 4th, 2024
- Researchers map 50,000 of DNAs mysterious knots in the human genome - EurekAlert - September 4th, 2024
- Artificial selection of mutations in two nearby genes gave rise to shattering resistance in soybean - Nature.com - September 4th, 2024
- Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany - Marketscreener.com - April 7th, 2023
- Molecular Genetics and Metabolism | Journal - ScienceDirect - December 11th, 2022
- People don't mate randomly but the flawed assumption that they do is an essential part of many studies linking genes to diseases and traits - The... - November 25th, 2022
- Molecular and Cell Biology and Genetics - Master of Science / PhD ... - October 7th, 2022
- NIPD Genetics: Leading Genetic Testing Company - October 7th, 2022
- Skeletal Biology and Regeneration Students Recognized For Research Excellence - UConn Today - University of Connecticut - October 7th, 2022
- Mary Munson elected fellow of the American Society for Cell Biology - UMass Medical School - October 7th, 2022
- Every Body's Talking at Them: an Interview with Jon Lieff - CounterPunch - October 7th, 2022
- TriBeta invites students to explore opportunities to work with faculty at research fair on Oct. 11 - Ohio University - October 7th, 2022
- Genetics: the Vatican Does Not Intend to Be Behind the Times - FSSPX.News - October 7th, 2022
- Yield10 Bioscience Appoints Willie Loh, Ph.D., to the Board of Directors - citybiz - October 7th, 2022
- Molecular pathways of major depressive disorder converge on the synapse | Molecular Psychiatry - Nature.com - October 7th, 2022
- Sigyn Therapeutics Strengthens Board of Directors With the Appointments of Richa Nand, Jim Dorst and Christopher Wetzel - Yahoo Finance - October 7th, 2022
- UTHSC Researcher Co-Leads Study of Genes that Modulate Aging, Lifespan - UTHSC News - UTHSC News - October 7th, 2022
- GATC Health Investor Conference to Feature First Public Demonstration of Its AI Platform's Drug Discovery Capabilities - PR Newswire - October 7th, 2022
- Three Professors Conferred Tenure and Eleven Promoted - Wesleyan Argus - October 7th, 2022
- Who will get the call from Stockholm? It's time for STAT's 2022 Nobel Prize predictions - STAT - October 7th, 2022
- Dalhousie to present exhibition celebrating Gerhard Herzberg and his legacy - Dal News - October 7th, 2022
- Why Some People Should Rethink Their Morning Cup Of Coffee - Health Digest - October 7th, 2022
- Cell and Gene Therapy: Rewriting the Future of Medicine - Technology Networks - October 7th, 2022
- UofL researchers lead the call to increase genetic diversity in immunogenomics - uoflnews.com - July 6th, 2021
- In Brief This Week: Foundation Medicine, Myriad Genetics, Genetron Health, and More - GenomeWeb - July 6th, 2021
- More filling? Tastes great? How flies, and maybe people, choose their food - Yale News - July 6th, 2021
- Genetic mapping of subsets of patients with fragile X syndro | TACG - Dove Medical Press - July 6th, 2021
- What is The Babydust Method? Danielle Lloyd swears method helped her conceive girl - The Mirror - July 6th, 2021
- Datar Cancer Genetics joins hands with US based Iylon Precision Oncology to offer personalized Precision Oncology cancer treatment solutions - PR Web - July 6th, 2021
- Mapping a pathway to competitive production - hortidaily.com - hortidaily.com - July 6th, 2021
- Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. - Physician's Weekly - July 6th, 2021
- Global Genomics Market | Rising Incidence of Chronic and Genetic Diseases are Key Factors to Grow Market During 2021-2029 | 23andMe, Agilent... - July 6th, 2021
- The Babydust Method Danielle Lloyd used to conceive a girl after four sons and how it works - RSVP Live - July 6th, 2021
- In the beginning science and faith - The Irish Times - June 24th, 2021
- Ancient Maya Maintained Native Tropical Forest Plants around Their Water Reservoirs | Archaeology - Sci-News.com - June 24th, 2021
- Local foundation awards $1.25 million to MIND Institute to study rare genetic condition - UC Davis Health - June 24th, 2021
- Xlife Sciences AG: Collaboration with the University of Marburg - Yahoo Finance - June 24th, 2021
- Genetics diagnostics in India is on the verge of transformation: Neeraj Gupta, Founder and CEO of Genes2me - The Financial Express - June 24th, 2021
- Precision Medicine: Improving Health With Personalized Solutions - BioSpace - June 24th, 2021
- Half of Portland areas 22 top National Merit winners hail from just 2 schools - OregonLive - June 24th, 2021
- Investing in stem cells, the building blocks of the body - MoneyWeek - June 24th, 2021
- New study finds low levels of a sugar metabolite associates with disability and neurodegeneration in multiple sclerosis - Newswise - May 14th, 2021
- Cernadas-Martn Is a Champion for Marine and Human Diversity | | SBU News - Stony Brook News - May 14th, 2021
- Four Penn Faculty: Election to the National Academy of Sciences - UPENN Almanac - May 14th, 2021
- Is there a difference between a gene-edited organism and a 'GMO'? The question has important implications for regulation - Genetic Literacy Project - May 14th, 2021
- 5 Students Inducted Into American Society for Biochemistry and Molecular Biology Honor Society - Wesleyan Connection - May 14th, 2021
- The Science of Aliens, Part 2: What Kind of Genetic Code Would Extraterrestrials Have? - Air & Space Magazine - May 14th, 2021
- UT Austin Faculty Member Receives 2021 Piper Professor Award - Office of the Executive Vice President and Provost - UT News | The University of Texas... - May 14th, 2021
- Distinguished University of Birmingham plant scientist elected to the Royal Society - University of Birmingham - May 14th, 2021
- Double Hoo Research: Undergrads and Grads Team Up to Create Knowledge - University of Virginia - May 14th, 2021
- Global Genetic Testing Market Top Countries Analysis and Manufacturers With Impact of COVID-19 | 2021-2028 Detail Analysis focusing on Application,... - May 14th, 2021
- Morag Park named to the Order of Quebec - McGill Reporter - McGill Reporter - May 14th, 2021
- Third Rock Ventures Launches Flare Therapeutics With $82 Million Series A - BioSpace - May 14th, 2021
- The Royal Society announces election of new Fellows 2021 - Cambridge Network - May 14th, 2021
- Researchers Decode the "Language" of Immune Cells - Technology Networks - May 14th, 2021
- RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map -... - May 14th, 2021
- Mice Sperm Sabotage Other Swimmers With Poison | Smart News - Smithsonian Magazine - February 14th, 2021
- Study Identifies Never-Before-Seen Dual Function in Enzyme Critical for Cancer Growth - Newswise - February 14th, 2021
- Devious sperm 'poison' their rivals, forcing them to swim in circles until they die - Livescience.com - February 14th, 2021
- More needs to be done to find and fight COVID-19 variants, says Colorado researcher - FOX 31 Denver - February 14th, 2021